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Abstract
Anti-Dopamine-2 receptor (D2R) antibodies have been recently identified in a subgroup of children with autoimmune
movement and psychiatric disorders, however the epitope(s) and mechanism of pathogenicity remain unknown. Here
we report a major biological role for D2R extracellular N-terminus as a regulator of receptor surface availability, and as a
major epitope targeted and impaired in brain autoimmunity. In transfected human cells, purified anti-D2R antibody
from patients specifically and significantly reduced human D2R surface levels. Next, human D2R mutants modified in
their extracellular domains were subcloned, and we analyzed the region bound by 35 anti-D2R antibody-positive
patient sera using quantitative flow cytometry on live transfected cells. We found that N-glycosylation at amino acids
N5 and/or N17 was critical for high surface expression in interaction with the last 15 residues of extracellular D2R
N-terminus. No anti-D2R antibody-positive patient sera bound to the three extracellular loops, but all patient sera
(35/35) targeted the extracellular N-terminus. Overall, patient antibody binding was dependent on two main regions
encompassing amino acids 20 to 29, and 23 to 37. Residues 20 to 29 contributed to the majority of binding (77%, 27/35),
among which 26% (7/27) sera bound to amino acids R20, P21, and F22, 37% (10/27) patients were dependent on
residues at positions 26 and 29, that are different between humans and mice, and 30% (8/27) sera required R20, P21,
F22, N23, D26, and A29. Seven patient sera bound to the region 23 to 37 independently of D26 and A29, but most sera
exhibited N-glycosylation-independent epitope recognition at N23. Interestingly, no evident segregation of binding
pattern according to patient clinical phenotype was observed. D2R N-terminus is a central epitope in autoimmune
movement and psychiatric disorders and this knowledge could help the design of novel specific immune therapies
tailored to improve patient outcome.
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Introduction
Dopamine receptor expression and innervation are prom-
inent in the brain, and are involved in the regulation of
neuromuscular and psychological functioning, including
gross and fine motor control, behaviour, learning, and
working memory [3]. In humans, dopamine-2 receptor
(D2R) is one of five dopamine receptors (DR), which are
rhodopsin-like seven transmembrane G-protein coupled
receptors (GPCR) belonging to the catecholamine sub-
family. The five subtypes of DR are divided into D1-like
group (D1R, D5R), and D2-like group (D2R, D3R, D4R)
based on their structural, biochemical, and pharmaco-
logical properties [2, 3]. Dopamine receptors share similar
structural features, including seven transmembrane do-
mains, an extracellular N-terminal domain, three extracel-
lular loops, three intracellular loops, and an intracellular
C-terminal domain [2, 37]. D1- and D2-like receptors
have high expression in the cortex, hippocampus, basal
ganglia, such as the striatum and the substantia nigra, and
they differ in their ability to modulate cyclic AMP (cAMP)
production [3].
Dopaminergic dysregulation has been related to multiple
disorders, such as schizophrenia, bipolar disorders, depres-
sion, and movement disorders such as Parkinsonism and
Tourette syndrome [3, 19]. The pathophysiology of some
of these disorders is poorly understood, however the im-
mune system may play a role in some patients with these
conditions. Recently, a subgroup of pediatric patients was
found to harbor specific autoantibodies against D2R, and
that association was accompanied by a spectrum of move-
ment and psychiatric disorders of suspected autoimmune
aetiology [13]. They are detected in the majority of chil-
dren with basal ganglia encephalitis (an inflammatory basal
ganglia syndrome with dystonia-parkinsonism), a signifi-
cant minority of Sydenham chorea (a post-streptococcal
autoimmune syndrome), and a small subgroup of patients
with Tourette syndrome and acute onset psychosis. Com-
mon to all patients is the presence of movement and psy-
chiatric disturbances. These patients with autoimmune
movement and psychiatric disorders often have post-
infectious onset and improve with early immune suppres-
sive or immune modulating therapies [13, 41], suggesting
that an immune-mediated process occurs.
Although the physiology and function of the DRs are
relatively well known, little is understood of D2R extracel-
lular N-terminal domain and its role in disease. In the
present study, we explored the function and influence of
D2R N-terminal residues and N-glycosylation sites re-
sponsible for protein export to the cell surface. Further-
more, we define specific residues of the D2R N-terminus
as targets of pathogenic autoantibodies in movement and
psychiatric disorders [48], providing novel therapeutic tar-
gets for patients affected by anti-D2R antibody-associated
autoimmune disorders.
Materials and methods
Patient and controls samples
Serum was collected from pediatric anti-D2R antibody-
positive patients (n = 35) with autoimmune movement
and psychiatric disorders (MPD) who have been recruited
locally, interstate, and internationally: basal ganglia
encephalitis (BG, defined as in [13], n = 15), post-herpes
simplex virus encephalitis autoimmune movement dis-
order (HEM, defined as in [35], n = 3), Sydenham chorea
(SC defined as [8], n = 12), first episode of psychosis (FEP
defined as [41], n = 2), and Tourette syndrome (TS, fulfilled
DSM-IV criteria for Tourette syndrome, n = 3) (Table 1).
Some patients (n = 29) had been identified as anti-D2R
antibody-positive in previous studies [13, 35, 41, 44]
(Table 1) and additional patients (n = 6) were newly identi-
fied as anti-D2R antibody-positive using our flow cyto-
metry live cell-based assay [1]. All patients were defined
positive as >3SD above the mean of 32 non-inflammatory
controls. Ethics approval for this study was granted by the
Sydney Children’s Hospital Network Human Research
Ethic Committee (HREC 2007/035, HREC 09/CHW/56,
and HREC 12/SCHN/395), and written informed consent
from all patients was obtained. BG sera used in antibody
studies was from the first week of acute admission, and be-
fore immune therapy. SC sera were taken during active
chorea in all patients. Blood sampling for FEP sera oc-
curred at median of 5 weeks and mean of 14.3 weeks after
psychosis symptom onset [41]. TS patients had active tic
disorders at the time of serum sampling (Table 1).
Control sera (n = 32) shown in Fig. 1 were obtained
from healthy children (CTL), children with other neuro-
logical disease, such as epilepsy and cerebral palsy
(OND), and first episode of demyelination (DEM). Con-
trol (CTL) sera (n = 32) shown in Fig. 2 were obtained
from children with epilepsy, cerebral palsy, neurometa-
bolic disease and neurodegenerative disorders (median
age 11 years, range 2-14).
Patient sera had immunoglobulin G (IgG) concentra-
tions measured by nephelometry (BN ProSpec, Siemens,
Germany), and IgG values were within the normal range
(6.2-14.4g/l).
Table 1 Clinical and demographic characteristics of children






Sydenham Chorea 12 9.5 (1–13) [13]




3 4 (1–6) [35]
Tourette Syndrome 3 8 (5–8) [13]
First episode psychosis 2 16 (15–17) [41]
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Human dopamine receptor mutants
Serum binding to human wild-type D2R (WT D2R), and
seven D2R mutants (NTermD1RχD2R, L Δ2-22, N5Q/
N17Q/N23Q, N23Q, D26E/A29P, N23Q/D26E/A29P
and L R20K/P21G/F22W/N23Q/D26E/A29P) was
analyzed. The mutations are shown in Figs. 2, 3, 4, 5, 6,
and 7. All patient sera recognized the native conform-
ation of WT D2R expressed on the surface of live cells.
To discriminate between binding to the D2R extracellu-
lar N-terminus or the extracellular loops, we created the
chimera NTermD1RχD2R, in which the entire extracellular
N-terminus of D2R was substituted with the one of
D1R, so we could analyse antibody immunoreactivity to
D2R extracellular loops. Additionally, we created Δ2-22
D2R (deletion of amino acids 2-22 of the N-terminal
extracellular domain), and Δ23-37 D2R (deletion of
amino acids 23-37 of the N-terminal extracellular do-
main) to define anti-D2R antibody binding to either the
first or second half of D2R N-terminus. However, we
found that the level of surface expression for both
constructs were low compared to WT D2R. Therefore
we subcloned L Δ2-22 D2R and L Δ23-37 D2R with a
cleavable signal peptide, called Lucy (L), to aid in cell
surface expression. In order to determine the contribu-
tion of N-linked glycosylation in antibody recognition,
we created N5Q/N17Q/N23Q, in which all glycosylation
sites (N5, N17, and N23) were mutated, and N23Q D2R
mutant, in which only one glycosylation site at position
N23 was mutated. As some human autoantibodies do
not recognize mouse equivalent antigen, for example
Fig. 1 Patient anti-D2R IgG antibodies induce receptor internalization and decrease D2R surface density. a, b Anti-D2R antibody-positive movement and
psychiatric disorder (MPD, n= 3) protein G-purified IgG from patients with similar ΔMFIs (14,388; 14,789; and 18,740, Fig. 2e) induces a downregulation of
surface D2R on live cells compared to IgG purified from control (CTL, n = 2), other neurological disorders (OND, n = 2), and demyelinating diseases
(DEM, n = 2). c Anti-D2R antibody-positive MPD (n = 3) protein G-purified IgG-incubated on live cells have a similar expression of cytoplasmic GFP
compared to IgG purified from CTL (n = 2), OND (n = 2), and DEM (n = 2). d, e MPD protein G-purified IgG and IgG purified from CTL have no effect
on surface NCAM (expressed in all HEK293 cells). Representative images are shown (volume projection of entire Z-stack). Nuclei stained with dapi
(scale bar = 25μm). 80 different cells (1 cell = 1 diamond) for each control and patient out of three independent experiments are shown. Results are
expressed as fluorescence intensity relative to culture medium (100%) after normalization to GFP and red bars represent mean. Data was analyzed by
Mann-Whitney U test, *P < 0.0001
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human anti-myelin oligodendrocyte glycoprotein (MOG)
antibodies do not bind to mouse MOG [33], we
generated the mutant D26E/A29P to murinize D2R
extracellular N-terminus. Based on results observed after
binding to D26E/A29P and N23Q, the triple mutant
N23Q/D26E/A29P was generated. As there is a high
level of conservation of amino acids 20 to 23 in mam-
mals (Additional file 1: Figure S3), we also generated L
R20K/P21G/F22W/N23Q/D26E/A29P mutant with six
point mutations in the extracellular N-terminus.
Molecular cloning of human D2R mutants
Extracellular N-terminus haemagglutinin (HA) tagged
human D1R and D2R were obtained from the Missouri
S&T cDNA Resource centre (www.cdna.org). We used
HA-tagged Syntaxin 4 as a control to exclude immuno-
reactivity of sera against the HA tag. All sera used in this
study were reactive to human D2R, but not to the HA
tag ([13], data not shown). Furthermore, studies using
HA-tagged GPCRs have shown that the presence of the
HA tag at the start of the extracellular N-terminus did
Fig. 2 Patient antibodies do not bind to the three extracellular loops of D2R or to D1R extracellular N-terminus. a, b Open reading construct
of WT D2R, and NTermD1RχD2R constructs in which the extracellular N-terminus of D2R was swapped for the extracellular N-terminus of D1R.
M =methionine; AA = amino acid; Red = 3x haemagglutinin (HA) tag; Blue = D2R sequence; Pink = D1R sequence; TM1 = first transmembrane
domain; I1 = first intracellular loop; Green = N-glycosylation site. c Confocal images after live immunolabeling of WT D2R or NTermD1RχD2R-transfected
HEK293 cells using an anti-HA antibody showed similar levels of cell surface expression for both constructs (scale bar = 50 μm). d Similar cell surface
expression of WT D2R and NTermD1RχD2R constructs was also confirmed by flow cytometry on live cells. No D2R expression from empty vector was
observed. Representative data out of three independent experiments is shown. e Sera from controls (CTL; n = 32) and movement and psychiatric
disorders (MPD; n = 35) were incubated with empty vector- and WT D2R-transfected live HEK293 cells at 1:50 dilution, followed by AF647-conjugated
anti-human IgG secondary antibody, and flow cytometry analysis. Anti-D2R antibody was detected in 35/35 MPD and 0/32 controls. f Sera from CTL
(n = 32) and anti-D2R antibody-positive MPD (n = 35) were incubated with empty vector- and NTermD1RχD2R-transfected live HEK293 cells at 1:50
dilution, followed by AF647-conjugated anti-human IgG secondary antibody, and flow cytometry analysis. Antibodies against the three D2R extracellular
loops or the D1R extracellular N-terminus were detected in 0/35 MPD and 0/32 controls. Δ mean fluorescence intensity (ΔMFI) was calculated using MFI
obtained with empty vector- and WT D2R- and NTermD1RχD2R-transfected HEK293 cells. Positivity threshold was determined by ΔMFI of three SD above
the mean of CTL (solid line on graph). Representative dot plot out of three experiments is shown
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Fig. 3 (See legend on next page.)
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not interfere with receptor ligand binding, and receptor ac-
tivation and signaling [42, 43]. Human D1R and D2R
cDNA were subcloned into pIRES2-GFP vector (Clontech),
a bicistronic plasmid containing an internal ribosome entry
site (IRES), allowing simultaneous expression of green
fluorescence protein (GFP) and the antigen of interest, as
described previously [1]. To obtain NTermD1RχD2R mutant,
we subcloned the extracellular N-terminus of D1R from
pIRES2-GFP HA D1R construct into pIRES2-GFP HA
D2R. Synthesized mini D2R cDNA (Blue Heron) were sub-
cloned into pIRES2-GFP HA D2R using NheI and PstI to
generate pIRES2-GFP HA Δ2-22 D2R, pIRES2-GFP HA
Δ23-37 D2R, pIRES2-GFP HA N23Q D2R, pIRES2-GFP
HA N5Q/N17Q/N23Q D2R, pIRES2-GFP HA D26E/
A29P D2R, pIRES2-GFP HA N23Q/D26E/A29P D2R, and
pIRES2-GFP HA R20K/P21G/F22W/N23Q/D26E/A29P
D2R. The cleavable signal peptide L (ATGAGACCCCA
GATCCTGCTGCTCCTGGCCCTGCTGACCCTAGGCC
TGGCT) [47] was inserted by PCR in pIRES2-GFP HA
Δ2-22 D2R, pIRES2-GFP HA Δ23-37 D2R, and pIRES2-
GFP HA R20K/P21G/F22W/N23Q/D26E/A29P D2R con-





GGTCTGCAGCGCC-3’. The oligonucleotides used to








CC-3’ for pIRES2-GFP HA FLAG L Δ2-22 D2R constructs,
which included FLAG tag (ATGGACTACAAGGAC
GACGATGACAAG). Purified plasmids were sequenced at
the Australian Genome Research Facility to confirm correct
plasmid sequences.
Analysis of antibody binding using flow cytometry live
cell-based assay
Human D2R constructs were transiently transfected and
expressed in human embryonic kidney 293 (HEK293)
cells as previously described [13, 41]. All mutant trans-
fections led to a transfection yield of 30-40%. Surface
expression of D2R constructs was confirmed by flow cy-
tometry on live cells. In all experiments, expression of
WT D2R reached 156,000 ± 29,486 mean fluorescence
intensity (MFI) at 100 ng/ml of anti-HA antibody and
162,429 ± 8174 MFI at 500 ng/ml. If D2R mutant surface
expression was below 80% of the WT D2R, then a L signal
peptide was attached. If the addition of the L signal pep-
tide did not successfully promote D2R mutant expression
above 80% of WT D2R, they were not included in our
analysis (i.e. L Δ23-37 mutant). A flow cytometry live cell-
based assay was used to detect antibody binding from
patient sera to transfected HEK293 cells. In Fig. 2e,
experiments were performed as previously described
[1, 5, 6, 41]. Additionally, six sera from D2R antibody-
positive patients (selected for adequate volume of serum
available) were serially incubated with five wells of live WT
D2R- and NTermD1RχD2R-transfected HEK293 cells [41].
Immunolabeling was assessed by flow cytometry cell-based
assay. To analyze epitope binding, each anti-D2R antibody-
positive serum was separately incubated concomitantly with
three types of cells in the same experiment: cells transfected
with human WT D2R, empty vector, and D2R mutant.
Binding percentage was determined using the formula:
binding % ¼ MFIðD2R mutantÞ−MFIðempty vectorÞMFIðWT D2RÞ−MFIðempty vectorÞ  100%:
Highly transfected cells with high GFP expression between
103-104 were analyzed. MPD patient sera were always
(See figure on previous page.)
Fig. 3 The majority of patient antibodies bind to a region encompassing amino acids 23-37 of D2R extracellular N-terminus. a Open reading
construct of WT D2R, Δ2-22 (D2R missing amino acids 2-22 of extracellular N-terminus), L Δ2-22 (Δ2-22 with additional cleavable Lucy (L) signal
peptide), FLAG L Δ2-22, FLAG Δ2-22, Δ23-37 D2R (D2R missing amino acids 23-37 of D2R extracellular N-terminus), L Δ23-37 D2R (Δ23-37 with
additional cleavable L signal peptide). M =methionine; AA = amino acid; Red = 3x haemagglutinin (HA) tag; Blue = D2R sequence; Purple = FLAG
sequence; TM1 = first transmembrane domain; I1 = first intracellular loop; Green = N-glycosylation site. b Confocal images after live immunolabeling of
WT D2R and mutant-transfected HEK293 cells using an anti-HA antibody showed decreased cell surface expression of Δ2-22 and Δ23-37 compared to
WT D2R. Introduction of a L signal peptide in Δ2-22, but not in Δ23-37, significantly increased surface expression to levels observed in WT D2R (scale
bar = 50 μm). c Increase of surface expression on live L Δ2-22-transfected HEK293 cells was confirmed by flow cytometry. Representative data out of
three independent experiments is shown. d Lack of rescue of surface expression on live L Δ23-37-transfected HEK293 cells was confirmed by flow
cytometry. Representative data out of three independent experiments is shown. e, f Confocal imaging and flow cytometry analyses after
live immunolabeling of FLAG L Δ2-22- and FLAG Δ2-22-transfected HEK293 cells showed successful L signal peptide cleavage in FLAG L Δ2-22-transfected
HEK293 cells (GFP staining not shown in overlay) (scale bar = 50 μm). g Schematic of L Δ2-22 D2R at cell surface. Red = 3xHA tag; Green =N-glycosylation
site; Blue = D2R sequence. h Sera from anti-D2R antibody-positive movement and psychiatric disorders (MPD, n = 35) were incubated with empty
vector-, WT D2R-, and L Δ2-22-transfected live HEK293 cells at 1:50 dilution, followed by AF647-conjugated anti-human IgG secondary antibody, and
flow cytometry analysis. Percentage of sera binding to L Δ2-22 (MFI %) was calculated using the formula described in Material and Methods. 71%
patients (25/35) recognized L Δ2-22 (518 ± 683%, n = 25), whereas 29% (10/35) showed no immunoreactivity to amino acids 23-37. Binding threshold
is represented by solid line on graph. Representative data out of three experiments is shown
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positive for the difference in MFI between WT D2R and
empty vector (denominator in formula). Therefore negative
binding percentages reflect the inability of anti-D2R
antibodies from the patient to bind to the D2R mutant.
Binding of patient sera to our different constructs was ana-
lyzed in three independent experiments. Surface expression
curves and dot plots were generated using Prism software
version 6 (GraphPad Software, La Jolla, CA). Flow cytome-
try data were acquired on a BDLSRII (BDBiosciences) flow
cytometer, and analysis was performed using Flowjo v7.5
software (TreeStar, Ashland, Oregon) and Excel (Microsoft,
Redmond, Washington).
Culture and differentiation of human neural stem
cell-derived neurons
GIBCO human neural stem cells (H9 hESC-derived) (Life
Technologies) were cultured and differentiated into
neurons according to manufacturer’s instructions. Briefly,
neural stem cells were cultured on CellStart-coated
(1:100) culture dish in complete serum-free human neural
stem cell culture medium (StemPro NSC SFM). To differ-
entiate neural stem cells into neurons, cells were plated
on a poly-L-ornithine and laminin-coated culture dish in
complete StemPro NSC SFM. After two days, medium
was switched to neural differentiation medium, which was
Fig. 4 Point mutation of D2R third N-glycosylation site does not abolish anti-D2R antibody binding. a Alignment of extracellular N-terminal 37
amino acids of N23Q and WT D2R. Green = putative N-glycosylation sites; Red = N to Q point mutation. b Schematic of N23Q at cell surface.
Red = 3xHA tag; Green = N-glycosylation site; Blue = D2R sequence; Purple = point mutation. c, d Confocal images and flow cytometry analysis
after live immunolabeling of WT D2R and N23Q-transfected HEK293 cells with an anti-HA antibody showed a similar level of surface expression
for both constructs (scale bar = 50 μm). No D2R expression from empty vector was observed. Reduced surface expression of N5Q/N17Q/N23Q
was observed. Representative data out of three independent experiments is shown. e Loss of N-linked glycan and decrease in molecular weight was
detected by western blot analysis in untreated (left panel) and tunicamycin-treated (right panel) WT D2R-, N23Q-, and N5Q/N17Q/N23Q-transfected
HEK293 cells. Tunicamycin treatment led to blockade of glycosylation in all mutant-transfected cells. Representative data out of three experiments is
shown. f Deglycosylation led to impairment in trafficking and decreased cell surface expression of WT D2R, N23Q, and N5Q/N17Q/N23Q. g Sera from
anti-D2R antibody-positive movement and psychiatric disorders (MPD, n = 25) were incubated with empty vector-, WT D2R-, and N23Q-transfected live
HEK293 cells at 1:50 dilution, followed by AF647-conjugated anti-human IgG secondary antibody, and flow cytometry analysis. Percentage of sera
binding to N23Q (MFI %) was calculated using the formula described in Material and Methods. 88% patients (22/25) recognized N23Q, whereas
12% (3/25) showed no immunoreactivity to N23Q. Binding threshold is represented by solid line on graph. Representative data out of three
experiments is shown
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changed 3-4 days later. To expedite differentiation, 0.5
mM of dibutyryl cAMP was added to the differentiation
medium daily starting at day 7 of differentiation for
3 days.
HEK293 cells, primary murine hippocampal, and human
neural stem cells immunocytochemistry
HEK293 cells were immunolabeled in live and fixed/
permeabilized conditions [13]. Slides were imaged using
an inverted confocal microscope (63X 1.4 numerical
aperture oil immersion lens) (Leica, Germany) and ana-
lyzed using Image J v1.46 software (National Institutes
of Health, Bethesda, Maryland). Embryonic day 16.5
mouse hippocampal neurons were cultured as previously
described [13, 17]. Immunocytochemistry on live primary
murine neurons and human neural stem cell-derived neu-
rons were performed as previously described [13, 41].
Neurons were visualized through 100X 1.4 numerical
aperture oil immersion lens with an inverted Olympus
IX-70 microscope (DeltaVision Core, Applied Precision,
GE Healthcare, Washington) and a CoolSnap QE camera
(Photometrics, Tucson, Arizona). Images were acquired as
0.15 μm-thick 40 serial optical sections, then deconvolved
using DeltaVision SoftWoRx software, version 5.0.0
Fig. 5 Human antibodies bind to mouse D2R extracellular N-terminus with a lower immunoreactivity. a Amino acid sequences of extracellular
N-terminus of mouse D2R (D26E/A29P) and human WT D2R. Green = putative N-glycosylation sites; Red = amino acid change between species.
b Schematic of D26E/A29P at cell surface. Red = 3xHA tag; Green = N-glycosylation site; Blue = D2R sequence; Purple = point mutation. c Confocal
images after live immunolabeling of D26E/A29P-transfected HEK293 cells using an anti-HA antibody showed high levels of cell surface expression
(scale bar = 50 μm). d Similar cell surface expression between WT D2R and D26E/A29P constructs was also confirmed by flow cytometry on live cells.
No D2R expression from empty vector was observed. Representative data out of three independent experiments is shown. e Sera from anti-D2R
antibody-positive movement and psychiatric disorders (MPD, n = 25) were incubated with empty vector-, WT D2R -, and D26E/A29P-transfected live
HEK293 cells at 1:50 dilution, followed by AF647-conjugated anti-human IgG secondary antibody, and flow cytometry analysis. Percentage of sera
binding to D26E/A29P (MFI %) was calculated using the formula described in Materials and methods. 60% patients (15/25) recognized D26E/A29P,
whereas 40% (10/25) showed no immunoreactivity to D26E/A29P. Binding threshold is represented by solid line on graph. Representative data out of
three experiments is shown. f Patient sera stained live murine hippocampal neurons, but no difference was observed between high or low serum
binders to D26E/A29P mutant. g Patient sera did not stain live human neural stem cell-derived neurons, probably because these neurons did not
express D2R on cell surface when immunolabeled with commercial anti-D2R antibody (scale bar = 25 μm)
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(Applied Precision, GE Healthcare), and volume projec-
tions of the entire Z-series were generated and overlaid
using ImageJ. All procedures on animals were approved
by the Kids Research Institute and Children’s Medical
Research Institute animal ethics committee and con-
formed to the published code of practice of the National
Health and Medical Research Council of Australia.
Analysis of surface D2R downregulation
To determine whether human IgG from anti-D2R anti-
body patients and controls induced downregulation of cell
surface D2R, we quantified the fluorescence of surface
D2R after incubation of patient or control IgG with live
cells. We purified IgG from 50-100 μl of patient sera with
similar ΔMFIs (ΔMFIs: 14,388; 14,789; and 18,740 on
Fig. 2e) using protein G-agarose and Microcon (Millipore),
and obtained from 3.2 to 11.9μg/μl of purified IgG in a
total volume of 20μl. We chose WT D2R-transfected
HEK293 cells as they are commonly used in neuro-
pharmacology to study the effects of D2R agonists on re-
ceptor trafficking and internalization [29]. Surface D2R or
Neural Cell Adhesion Molecule (NCAM, surface adhesion
molecule used as control) on live WT D2R-transfected
HEK293 cells was labelled with anti-HA and anti-NCAM
antibodies, respectively, and appropriate secondary anti-
body for 30 min at room temperature. NCAM- and D2R-
labelled live cells were then incubated with 8μg of protein
G-purified human IgGs from patient or control sera, or
culture medium alone for 30 min or 2 h at room
temperature, or 30 min at 37°C. After washing, cells were
fixed and mounted, and cell surface D2R and NCAM
fluorescence was quantified using 3D-deconvolution mi-
croscopy. Importantly, both controls and patient-treated
cells received the same labelling with anti-HA or anti-
NCAM antibody in order to control the impact of antibody
binding on the receptor and provide suitable controls. For
quantification purposes, we have used 3D-deconvolution
algorithm on images acquired through the Deltavision Core
microscope, as previously described [14]. Levels of surface
D2R and NCAM were calculated by measuring the
average intensity per unit volume at the cell surface
after all Z-series were summed. D2R values were normal-
ized to GFP values and expressed as mean ± SD of fluores-
cence intensity relative to the “culture medium alone”
condition (100%). For consistency, NCAM was analyzed
in GFP-positive HEK293 cells, and values were also nor-
malized to GFP, although all HEK293 cells, transfected or
not, expressed surface NCAM. NCAM results were also
Fig. 6 Patient antibody recognise mouse D2R when N23 is deglycosylated. a Amino acid sequences of extracellular 37 amino acids of N23Q/
D26E/A29P and WT D2R. Green = putative N-glycosylation sites; Red = amino acid changes. b Schematic of N23Q/D26E/A29P at cell surface.
Red = 3xHA tag; Green = N-glycosylation site; Blue = D2R sequence; Purple = point mutation. c Confocal images after live immunolabeling of
N23Q/D26E/A29P- transfected HEK293 cells using an anti-HA antibody (scale bar = 50 μm). d Similar cell surface expression of N23Q/D26E/A29P
and WT D2R constructs was confirmed by flow cytometry on live cells. No D2R expression from empty vector was observed. Representative data
out of three independent experiments is shown. e Sera from anti-D2R antibody-positive movement and psychiatric disorders (MPD, n = 25) were
incubated with empty vector-, WT D2R -, and N23Q/D26E/A29P-transfected live HEK293 cells at 1:50 dilution, followed by AF647-conjugated
anti-human IgG secondary antibody, and flow cytometry analysis. Percentage of sera binding to N23Q/D26E/A29P (MFI %) was calculated using the
formula described in Material and Methods. 96% patients (24/25) recognized N23Q/D26E/A29P, whereas 4% (1/25) showed no immunoreactivity to
N23Q/D26E/A29P. Binding threshold is represented by solid line on graph. Representative data out of three experiments is shown
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expressed as fluorescence relative to the “culture medium
alone” condition (100%).
Western blot
D2R mutant-transfected HEK293 cells were lysed at 4°C
for 30 min with RIPA buffer (150 mM NaCl, 1% NP-40,
0.5% DOC, 0.1% SDS, 50 mM Tris pH 8) and 5 μl prote-
ase inhibitor (PI)/ml. Protein concentration in supernatant
was measured using BCA assay (Thermo Scientific) on a
plate reader. For experiments blocking N-linked glycosyla-
tion, media of transfected HEK293 cells were supple-
mented with 2 μg/ml of Tunicamycin. 2.5 μg of total
protein was loaded onto SDS gel and separated by gel
electrophoresis. The membrane was blocked in 4% milk
for 30 min, and incubated with anti-HA antibody (1:1000)
and mouse anti-vinculin antibody (1:1000) for 1 h at room
temperature then washed three times in 2% milk-PBS-
0.2% Tween 20. Next, the membrane was incubated in
anti-rabbit horseradish peroxidase (HRP)- and anti-mouse
HRP-conjugated secondary antibody (1:1000) for 1 h at
room temperature, then developed in ECL after washes.
Statistical analysis
Mann-Whitney U test was used to compare CTL and
MPD cohorts in Fig. 1. One-way analysis of variance
with a Dunn’s multiple comparison test was carried out
to analyze differences in binding percentage between
D2R mutants. P < 0.05 was considered significant.
Results
Human antibodies target surface D2R and purified IgG
causes surface D2R downregulation
We have previously shown that a subgroup of pediatric
patients with movement and psychiatric disorders (MPD)
were anti-D2R antibody-positive and that the antibodies
reacted towards an extracellular epitope of surface human
D2R, but not against surface D1R [13, 41]. To determine
whether anti-D2R IgG antibody would alter levels of
Fig. 7 Extracellular N-terminal amino acids 20-22 contribute to a major binding region. a Amino acid sequences of extracellular 37 amino acids of
R20K/P21G/F22W/N23Q/D26E/A29P and WT D2R. Green = putative N-glycosylation sites; Red = amino acid changes. b Schematic of R20K/P21G/
F22W/N23Q/D26E/A29P at cell surface. Red = 3xHA tag; Green = N-glycosylation site; Blue = D2R sequence; Purple = point mutation. c Similar cell
surface expression of L R20K/P21G/F22W/N23Q/D26E/A29P and WT D2R constructs was observed by flow cytometry on live cells, whereas R20K/
P21G/F22W/N23Q/D26E/A29P (without L signal peptide) has significantly decreased surface expression. No D2R expression from empty vector
was observed. Representative data out of three independent experiments is shown. d Confocal images after live immunolabeling of L R20K/
P21G/F22W/N23Q/D26E/A29P transfected HEK293 cells using an anti-HA antibody (scale bar = 50 μm). e Sera from anti-D2R antibody-positive
movement and psychiatric disorders (MPD) that bind L Δ2-22 (n = 25) or not (n = 10) were incubated with empty vector-, WT D2R-, and L R20K/P21G/
F22W/N23Q/D26E/A29P-transfected live HEK293 cells at 1:50 dilution, followed by AF647-conjugated anti-human IgG secondary antibody, and flow
cytometry analysis. Percentage of sera binding to L R20K/P21G/F22W/N23Q/D26E/A29P (MFI %) was calculated using the formula described in Material
and Methods. Among the group that bound L Δ2-22, 56% patients (14/25) recognized L R20K/P21G/F22W/N23Q/D26E/A29P, whereas 44% (11/25)
showed no immunoreactivity to the mutant. Among the group that did not bind L Δ2-22, 7/10 (70%) did not recognize L R20K/P21G/F22W/N23Q/
D26E/A29P mutant, whereas 3/10 (30%) did bind to it. Binding threshold is represented by solid line on graph. Representative data out of three
experiments is shown
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surface D2R, we used live transfected HEK293 cells that
express high levels of human WT D2R. Firstly, we tagged
surface D2R using anti-HA antibody on live WT D2R-
transfected HEK293 cells, and then incubated the cells
with 8 μg of protein G-purified IgG from controls (CTL),
other neurological disorders (OND), demyelinating
diseases (DEM) (positive for anti-MOG antibody [14]),
MPD anti-D2R antibody-positive sera with similar ΔMFIs,
or culture medium alone for 30 min or 2 h at room
temperature, or 30 min at 37 °C. Live and healthy looking
cells were then fixed and images were acquired using 3D-
deconvolution microscopy. We observed a statistically sig-
nificant decrease of surface D2R after incubation of live
cells with MPD IgG from all three anti-D2R antibody-
positive patients that were tested after 2 h incubation at
room temperature (Fig. 1a, b) (P < 0.0001, 59.5 ± 30%,
72.6 ± 40%, and 61.6 ± 32.7%), whereas levels of normal-
ized surface D2R were similar in CTL (98.7 ± 57.4% and
98.3 ± 38.6%) and OND (103.3 ± 48.3% and 107.1 ± 34%)
IgG-treated cells (Fig. 1a, b). Importantly, this effect fo-
cused on receptor downregulation from the surface as
cells were not permeabilized before immunolabeling. To
assess the specificity of this effect with MPD IgG, we incu-
bated live anti-HA antibody-tagged WT D2R-transfected
HEK293 cells with anti-MOG antibody-positive DEM IgG
(106.6 ± 49.9% and 108.2 ± 49.9%), and could not observe
any decrease in surface D2R (Fig. 1a, b). Levels of intracy-
toplasmic GFP were similar in all conditions tested
(Fig. 2c). This decrease in surface expression was not ob-
served when cells were incubated for 30 min either at
room temperature or at 37 °C (Additional file 1: Figure S1).
Furthermore, we also controlled whether levels of surface
NCAM, a molecule constitutively expressed at the surface
of HEK293 cells, were affected by incubation with IgG
from CTL and MPD. Incubation of CTL (109.9 ± 41.4%)
and anti-D2R antibody-positive MPD IgG (104.1 ± 44.7%)
did not induce any changes in levels of surface NCAM
(Fig. 1d, e), suggesting that MPD IgG specifically induced
D2R downregulation, and that this effect was through
binding of antibodies to extracellular domains of WT D2R.
Antibodies specifically target the extracellular N-terminal
domain of D2R
The extracellular domains of human WT D2R consist of
the N-terminus of 37 amino acids, and three extracellular
loops. We therefore examined which extracellular epi-
topes were recognised by MPD autoantibodies, using D2R
N-terminal deletion constructs and glycosylation mutants.
We first subcloned NTermD1RχD2R in which the entire
extracellular N-terminus of D2R was substituted with the
one of the closely related D1R (Fig. 2a, b). Surface expres-
sion of NTermD1RχD2R was found to be similar to WT
D2R (Fig. 2c, d). Next, we tested MPD anti-D2R antibody
specificity to NTermD1RχD2R by flow cytometry live cell-
based assay. We found that immunolabeling of live WT
D2R-transfected cells by NTermD1RχD2R-immunoabsorbed
sera was higher compared to their immunoabsorption on
WT D2R-transfected cells (Additional file 1: Figure S2),
and none of 35 MPD anti-D2R antibody-positive sera
(0%) (Fig. 2e) bound to NTermD1RχD2R (Fig. 2f), suggesting
that MPD antibodies do not bind to the extracellular
N-terminus of D1R or the extracellular loops of D2R.
Amino acids 23 to 37 include a major binding region for
anti-D2R IgG antibodies
To define anti-D2R antibody specificity within the 37
amino acids of D2R extracellular N-terminus, we split the
N-terminus into two sections. The first construct, called
Δ2-22, only included amino acids 23-37 of the N-terminus
followed by the remaining human WT D2R sequence
(Fig. 3a). The second construct, Δ23-37, only contained
amino acids 2-22 of D2R N-terminus followed by WT
D2R sequence (Fig. 3a). Both constructs (Δ2-22 and
Δ23-37), each lacking a portion of the D2R N-terminal
extracellular domain, showed reduced cell surface expres-
sion levels compared to WT D2R (Fig. 3b, c, d). As surface
expression influences the analysis of autoantibody epitope
binding, we attempted to increase Δ2-22 and Δ23-37 dele-
tion mutant surface expression by using a cleavable signal
peptide derived from T regulatory cell type 1 membrane
protein, Leucine-Rich Repeat Containing 32 (LRRC32),
named Lucy (L) because of its leucine-rich repeat regions
[47]. The L signal peptide was inserted before the HA tag
in L Δ2-22 and L Δ23-37 (Fig. 3a). The L signal peptide
significantly increased Δ2-22 trafficking to the surface:
from 68% surface expression for Δ2-22 (Fig. 3c, 107,167 ±
15,590 MFI, n = 3) to 101% for L Δ2-22 (Fig. 3c, 160,000 ±
12,832 MFI, n = 3) compared to 100% for WT D2R (Fig. 3c,
158,667 ± 2624 MFI, n = 3). In contrast, the addition of the
L signal peptide to Δ23-37 could not rescue surface expres-
sion (Fig. 3b, d), suggesting residues 23-37 are fundamen-
tally important for export of D2R through the secretory
pathway to the plasma membrane.
We next determined whether the L signal peptide was
cleaved before surface expression in order to assess the
risk of non-specific binding of autoantibodies to uncleaved
L signal peptide. A FLAG tag was added at the extreme
N-terminus of both L Δ2-22 and Δ2-22 (Fig. 3a). Both
FLAG L Δ2-22- and FLAG Δ2-22-transfected live
HEK293 cells expressed the surface mutant receptor as
detected after anti-HA antibody immunolabeling, with
FLAG L Δ2-22 D2R showing a higher surface expression
compared to FLAG Δ2-22 D2R (Fig. 3e), indicating that
the HA tag was present on the mature protein. However,
when FLAG L Δ2-22-expressing cells were surface labeled
using anti-FLAG antibody, the FLAG epitope was no lon-
ger present on the cell surface (Fig. 3e, f), suggesting that
the L signal peptide was a functional signal peptide
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cleaved early in the biosynthetic pathway, and therefore
not detectable at the cell surface. Interestingly, L Δ2-22
could not be immunolabeled by a commercial anti-D2R
antibody that targets the extracellular N-terminus, sug-
gesting that commercial anti-D2R antibody epitope lies
within amino acids 1-22 of D2R, and providing further ra-
tionale to use the HA tag to ensure correct surface trans-
port of mutants (Additional file 1: Figure S3).
The successful cleavage of the L signal peptide, accom-
panied by the increased surface expression of L Δ2-22
(Fig. 3g) to levels similar to WT D2R, enabled its use to
reliably assess autoantibody binding to residues 23-37.
We found 25/35 of anti-D2R antibody-positive MPD
patients (71%) bound to L Δ2-22, inferring that these
patients recognized an epitope within residues 23-37 (mean
binding: 518 ± 683%, n = 25) (Fig. 3h), whereas 10/35 (29%)
did not bind L Δ2-22 (mean binding: -171 ± 156%, n = 10)
(Fig. 3h). Several positive sera had a very high binding
(>300%, mean binding: 1015 ± 785%, n = 11), suggesting
that deletion of amino acids 2-22 could improve antibody
access to epitopes. The binding specificity was similar in all
disorders analyzed, and no clinical phenotype-specific bind-
ing could be observed (data not shown). This data suggests
that a major epitope(s) for MPD autoantibodies is con-
tained within the extracellular N-terminus of D2R encom-
passing residues 23-37.
Role of D2R N-Glycosylation in anti-D2R antibody binding
To further refine the specific antigenic region within resi-
dues 23-37 of D2R, recognised by two-thirds of our MPD
cohort, we next examined the effect of N-glycosylation as
it has been reported to influence D2R trafficking to the
cell membrane [11]. Indeed, targeted mutagenesis of all
three putative N-glycosylation sites (N5Q/N17Q/N23Q,
Additional file 1: Figure S4a) led to low cell surface ex-
pression and intracellular sequestration of the mutant
(Additional file 1: Figure S4). However, point mutation of
the third N-glycosylation site only (N23Q) (Fig. 4a, b) did
not affect cell surface expression, with levels of anti-HA
binding similar to WT D2R (Fig. 4c, d), thereby enabling
its use to assess patient antibody binding. Western blot
analysis confirmed the loss of the N-linked carbohydrate
on N23Q mutant (Fig. 4e), with a decrease of apparent
protein weight from 57kDa for WT D2R to 55kDa for
N23Q in similarly transfected HEK293 cells (Fig. 4e)
(ExpPASy Compute pI/Mw tool). N5Q/N17Q/N23Q was
only faintly observed as it is cytoplasmic and not
membrane-bound, and was not extracted with RIPA lysis
buffer (Fig. 4d, e, and Additional file 1: Figure S4b). Treat-
ment with the N-glycosylation inhibitor tunicamycin
(inhibitor of N-acetylglucosamine transferases) resulted in
the loss of N-linked carbohydrates on asparagines in WT
D2R and N23Q (Fig. 4e), but also an important loss of
surface trafficking (Fig. 4f), irrespective of the numbers of
putative N-glycosylation sites. These data confirm the
surface trafficking impairment of N5Q/N17Q/N23Q [11].
Importantly, our data demonstrate glycosylation at N23 is
not required for D2R export to the cell membrane,
whereas putative glycosylations at N5 and N17 would be.
We then tested the 25 patient sera previously shown to
bind to L Δ2-22, and found that 22/25 (88%) patients
recognized N23Q (mean binding: 139 ± 174%, n = 22),
whereas 3/25 (12%) patients did not bind to N23Q (mean
binding: -96 ± 75%, n = 3) (Fig. 4g). Similar to L Δ2-22,
binding was not associated to any specific clinical pheno-
type (data not shown). Thus, glycosylation at N23 is not
the likely basis for antigenicity within residues 23-37.
Human anti-D2R antibodies have reduced binding to
mouse D2R N-terminus
Human IgG specific to human antigens do not always
bind to the equivalent mouse antigen in demyelinating
diseases [33], and this can have consequences for patho-
genic studies in animal models. Thus, we created the
mutant D26E/A29P to emulate the mouse D2R extracel-
lular N-terminal domain (Fig. 5a, b). Importantly, amino
acids D26/A29 are located within amino acids 23-37, the
region relevant to patient antibody targeting. We found
D26E/A29P to be highly expressed at the cell surface
(Fig. 5c) which was comparable to WT D2R (Fig. 5d).
Binding analysis using the D26E/A29P mutant showed
that some patient sera (10/25, 40%) did not recognize
D26E/A29P mutant (mean binding: -69 ± 44%, n = 10),
whereas 15/25 (60%) patients bound to this construct
(mean binding: 87 ± 162%, n = 15) (Fig. 5e) with signifi-
cantly reduced binding compared to N23Q (P < 0.05).
Therefore, these data suggest that human patient auto-
antibodies may be species-specific, highlighting the im-
portance of amino acids D26/A29 in the formation of
the D2R antigenic determinant.
As immunolabeling of live murine neurons is recom-
mended in the current clinical algorithm for diagnosis of
autoantibody-associated disorders [22], we compared the
binding of anti-D2R antibody between immunolabeled
live murine primary neurons and human neural stem
cell-derived neurons (Fig. 5f, g). Patient sera stained
murine hippocampal neurons, but no obvious difference
was observed between patient sera that had high or low
binding to D26E/A29P mutant via the flow cytometry
live cell-based assay (Fig. 5f ), suggesting that other epi-
topes could be present in mouse D2R, especially within
the extracellular loops. Patient sera did not stain live hu-
man neural stem cell-derived neurons (Fig. 5g) that did
not express D2R on cell surface (Fig. 5g), supporting the
specificity of patient autoantibody binding to D2R.
As N23 is relatively close to D26/A29 in D2R linear
sequence, and the expression of D26E/A29P reduced
autoantibody binding, we created N23Q/D26E/A29P
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mutant (Fig. 6a, b), in which the N-glycosylation site at
N23 and human amino acids at positions 26 and 29 were
mutated. We found N23Q/D26E/A29P was highly
expressed at the cell surface (Fig. 6c, d). After analysis of
antibody binding, 24/25 (96%) patient sera bound to this
D2R mutant (mean binding: 93 ± 43%, n = 24) similarly
to N23Q (P > 0.05, Fig. 4g), and 1/25 (4%) did not
recognize this mutant (binding: -230%, n = 1) (Fig. 6e).
Amino acids 20-22 contribute to anti-D2R antibody
binding
10/35 of our MPD patient sera immunoreactive to the
D2R N-terminal extracellular domain did not recognise
L Δ2-22 (Fig. 3h), and likely recognize antigenic deter-
minants within residues 2-22. However, the influence of
amino acids 2-22 in antibody binding is difficult to
determine due to the lack of surface expression of L
Δ23-37 (including amino acids 2-22). Therefore, due to
the importance of amino acids 2-22 in receptor trafficking,
the need to keep the N-linked glycosylation conservative
site (N-X-S/T) of N17, and phylogenetic alignment of D2R
in higher vertebrate revealing that amino acids 20-22 are
highly conserved within the animal kingdom (Additional
file 1: Figure S5), we constructed R20K/P21G/F22W/
N23Q/D26E/A29P mutant (Fig. 7a, b), and used amino
acid changes found in different species that were unlikely
to modify the overall structure of D2R (Additional file 1:
Figure S5). Mutations of these six amino acids strongly de-
creased surface expression compared to WT D2R (Fig. 7c),
and L signal peptide was used to double the surface avail-
ability of R20K/P21G/F22W/N23Q/D26E/A29P mutant:
from 61% (96,000 MFI) to 141% (223,000 ± 4320 MFI) in
L R20K/P21G/F22W/N23Q/D26E/A29P compared to
WT D2R (100%) (Fig. 7c, d). We then analyzed patient
sera previously shown to bind to L Δ2-22 D2R (Fig. 3h),
and found that almost half of the patients (11/25, 44%)
did not bind to L R20K/P21G/F22W/N23Q/D26E/A29P
(mean binding: -137 ± 127%, n = 11), whereas 14/25 (56%)
recognized the mutant (mean binding: 50 ± 21%, n = 14)
(Fig. 7e). We tested the 10 patients who did not recognise
L Δ2-22 D2R mutant (Fig. 3h) with L R20K/P21G/F22W/
N23Q/D26E/A29P D2R as this subgroup of MPD patients
could potentially bind to amino acids at positions 20, 21,
22. We found that 7/10 (70%) did not recognize this
mutant (mean binding: -266 ± 208%, n = 7), whereas
3/10 (30%) did bind to this mutant (mean binding:
98 ± 36%, n = 3) (Fig. 7e). These results suggest that anti-
body binding is strongly dependent on amino acids 20-22.
Amino acids 20 to 29 form the major region bound by
anti-D2R antibodies
To summarize our data at the cohort level, we compared
binding percentages of the four D2R mutants that retained
the 37 amino acids of the extracellular N-terminus but
included point mutations within this region (Fig. 8). Bind-
ing was similar between N23Q (mean binding: 111 ±
182%, n = 25, P > 0.05) and WT D2R (100% binding).
Murinization of amino acids 26 and 29 strongly reduced
binding (mean binding: 24 ± 150%, n = 25, P < 0.01). Inter-
estingly, the deglycosylation was able to compensate the
murinization of position 26 and 29, as the N23Q/D26E/
A29P mutant (mean binding: 80 ± 76%, n = 25, P > 0.05)
was very similar to N23Q. L R20K/P21G/F22W/N23Q/
D26E/A29P mutant had the greatest impact on antibody
binding (mean binding: -32 ± 126%, n = 25, P < 0.001).
Overall, patient antibody binding was dependent on two
main regions encompassing amino acids 20 to 29, and 23
to 37 (Fig. 9a, b). The majority of sera (77%, 27/35, black
dotted line) bound to a region including amino acids 20 to
29, among which 26% (7/27, yellow) bound to amino acids
R20, P21, and F22, 37% (10/27, cyan and green) did not
bind to the murinized D2R N-terminus (D26E/A29P mu-
tant), and 30% (8/27, gray) required R20, P21, F22, N23,
D26, and A29 (Fig. 9b, c). Seven sera bound to the region
23 to 37 independently of D26 and A29 (magenta and
purple), of which two were dependent on N-glycosylation
at N23 (purple). Only a minority of sera (9%, 3/35, red)
recognized residues 1 to 19 (Fig. 9b, c). Interestingly, we
Fig. 8 Comparison of antibody binding to four full-length D2R
mutants. Binding was similar between N23Q and N23Q/D26E/A29P
mutants with WT D2R (100% binding shown as dotted line). Murinization
of amino acids 26 and 29 (D26E/A29P) strongly reduced binding.
Interestingly, L R20K/P21G/F22W/N23Q/D26E/A29P mutant had the
greatest impact on antibody binding. Percentage of sera binding to
D2R mutants (MFI %) was calculated using the formula described in
Material and Methods. Results are expressed as mean ± SD %. Data
was analyzed by one-way ANOVA analysis of variants with a Dunn’s
multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001
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could not observe any evident segregation of binding
pattern according to patient clinical phenotype (Fig. 9c).
Discussion
Using the human glycosylated native conformational
D2R, we show the importance of D2R extracellular
N-terminus in regulating receptor availability at the
cell surface, human anti-D2R antibody binding, and
potential pathogenic mechanisms of these antibodies.
Our study highlighted fundamental knowledge about the
D2R N-terminus, essential for correct receptor integration
into the plasma membrane. Receptor surface trafficking
was strongly decreased when N-terminal glycosylation sites
were removed. Blocking of N-glycosylation sites via
treatment of tunicamycin or obliteration of the three
N-glycosylation sites at positions N5, N17, and N23
inhibited receptor transport to the cell surface. These find-
ings support previous studies [11, 28, 34]. However, our
study shows that not only are the three glycosylation sites
not equal in ensuring correct receptor trafficking, but that
their influence is dependent on the amino acids included
in the N-terminus. Indeed, single point mutation that only
Fig. 9 Major binding regions of human anti-D2R antibody on D2R extracellular N-terminus. a Schematic of human D2R and extracellular N-terminal
amino acids of D2R involved in antibody binding. MPD patient antibody binding was dependent on binding regions centered on residues at positions
20 to 22 (yellow), 26 and 29 (green), and 23 to 37 (magenta). b Venn diagram of the main binding regions of 35 pediatric patient sera on human D2R
extracellular N-terminus. The black dotted line shown represents binding to residues 20 to 29 by the majority of sera (77%, 27/35). Binding to R20, P21,
and F22 is shown in yellow (26%, 7/27), and cyan and green groups represent immunoreactivity to D26 and A29 (37%, 10/27). Seven sera bound to
residues 23 to 37 (binding to L Δ2-22 D2R) excluding D26 and A29 (magenta and purple), among which two were dependent on N-glycosylation at
N23 (purple). Indeed, the magenta group bound to all D2R mutants modified at R20, P21, F22, N23, D26, and A29, suggesting binding outside these
residues. Red shows binding to residues 1 to 19 (9%, 3/35). The Venn diagram was compiled with data summarizing three independent experiments
illustrated by black and gray boxes shown in panel c. Amino acids (aa) bound by patient sera are shown in white text. c Table of binding patterns of
35 individual anti-D2R antibody-positive patient sera according to D2R mutants (columns) and clinical disorders (rows). Light gray boxes represent
binding to mutant and black boxes represent no binding. 10/35 patient sera did not bind to residues 23-37 (L Δ2-22 D2R), and therefore were not
tested on mutants encompassing these amino acids (white boxes). No clinical phenotype could be associated with a specific binding pattern. SC,
Sydenham chorea; BG, basal ganglia encephalitis; HEM, Post-herpes simplex virus encephalitis autoimmune movement disorder; TS, Tourette syndrome;
FEP, first episode psychosis. Colored boxes relate to Venn diagram in panel b
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abolished the third N-glycosylation site at residue N23 did
not affect surface expression, and the presence of the first
two putative N-glycosylated asparagines, N5 and/or N17,
could not compensate for the loss of residues 23 to 37. On
the other hand, the presence of amino acids 23 to 37 en-
sured cell surface expression, but only included one glyco-
sylation site (N23). Therefore, the identity, rather than the
number of residues, might also play a critical role in sur-
face receptor availability. Furthermore, trafficking to the
surface is influenced by the presence of a signal peptide or
signal anchor peptide (membrane insertion mediator) in
secretory or transmembrane proteins, respectively. Cleav-
able signal peptides are generally not present in mono-
amine GPCRs, such as D2R [53], but an uncleaved signal
anchor peptide is usually contained within the first trans-
membrane domain. In the case of human D2R, SignalP-
HMM V2.0 predicts the anchor peptide location between
Y36 and R61 [36]. Interestingly, removal of the first two
putative residues of the predicted 25 residues anchor pep-
tide in Δ23-37 D2R mutant influenced export to the sur-
face that was not boosted by the addition of the Lucy
signal peptide.
We assessed 35 anti-D2R IgG antibody-positive pa-
tient sera to evaluate the importance of amino acids in
D2R N-terminus immunoreactivity. Binding patterns of
the majority of patient sera was not associated with any
clinical phenotype, was highly dependent on amino acids
included between positions 20 to 29 (R20, P21, F22,
N23, D26, and A29), and the combination of modifica-
tions of residues at these positions had an additive effect
that strongly decreased autoantibody binding. While that
region was clearly essential for autoantibody binding,
only a third of patient sera bound to all of these six
amino acids, whereas a quarter of sera preferred R20,
P21, F22, and 37% preferred D26 and A29, suggesting
that not all of these six amino acids contribute equally
to epitope formation. Only a few patients had a strict
preference for binding at glycosylated asparagine (N23).
This is also the case for other neuroimmune auto-
antibodies such as anti-AMPAR, -Caspr2, and -MOG
antibodies, with only anti-NMDAR and -contactin anti-
bodies displaying a strong binding for N-linked carbohy-
drate [20, 21, 31, 33, 39, 49].
Differences in binding were observed between human
and mouse D2R N-terminal domains. We found that some
patients either did not recognize mouse D2R N-terminus,
or bound with a lower immunoreactivity, suggesting hu-
man autoantibodies may be species-dependent, as previ-
ously reported for human anti-MOG antibodies [33, 49].
Furthermore, our data from live mouse primary neurons
showed that there was no obvious difference between sera
with high and low mouse D2R N-terminus binding, sug-
gesting additional epitopes within the extracellular loops of
mouse D2R, or any other posttranslational modifications
on neurons, but not present or recognized in human D2R.
Although recent guidelines for the identification of
antibody-associated brain disorders recommend confirma-
tory assays on live neurons and rodent tissues [22], our
findings also suggest that some human autoantibody-
positive patients might be missed when screening with ro-
dent neurons and tissues. The use of primary cultures of
human stem cell-derived neurons is also difficult and not
the most appropriate replacement for human non neuronal
cell lines to investigate binding specificity between species,
but also for pathogenic studies, mainly due to their lack of
expression of D2R.
Taking the species specificity into account, we investi-
gated the mechanisms of anti-D2R antibody pathogenicity
using HEK293 cells expressing conformational human
D2R, and an experimental system widely used in neuro-
pharmacology in which cells produced high levels of D2R.
We found significant antibody-mediated specific down-
regulation of surface D2R with patient samples compared
to controls. This receptor downregulation may be patho-
logically relevant in patients with movement and psychi-
atric disorders. Dopamine binding to D2R is followed by
surface D2R downregulation from the cellular membrane
leading to dynamic regulation and resensitization [3]. We
hypothesize that anti-D2R antibody-mediated downregu-
lation of surface D2R may alter dopamine signalling in
patients. Indeed, a similar receptor internalization effect
has previously been reported in anti-NMDAR encephalitis
and anti-AMPAR encephalitis [15, 24, 32], and is likely to
be an important mechanism of pathogenic neuroimmune
autoantibodies in general. To support anti-D2R antibody
pathogenicity, patients show improvements after treat-
ment with immunotherapies [13]. Animal transfer ex-
periments could validate human anti-D2R antibody
pathogenicity, as demonstrated for anti-AQP4 antibody in
neuromyelitis optica [30] and anti-NMDAR antibody in
encephalitis [45, 54]. However, the difference in epitope
binding between human and mouse D2R could influence
the relevance of results obtained in animal studies.
Antibody polyclonality, defined by binding to a range
of epitopes, is theoretically plausible in human serum
samples, and indeed has been suggested in the cases of
anti-AQP4 and -MOG antibody-positive patient sera
[25, 33]. Although this hypothesis is difficult to demon-
strate, the immunoreactivity of the eight patients who
bound the six residues 20, 21, 22, 23, 26, and 29 (gray
group) could indeed reflect two binding contributions;
residues 20 to 23, and residues 26 and 29. Therefore,
some binding patterns and the fact that antibody binding
could not be completely abrogated may suggest the ex-
istence of polyclonality for at least a subgroup of anti-
D2R antibody-positive patients.
Further insights into autoantibody epitope recognition
have been informed by the resolution of the structural
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biology of the autoantigen. In particular, three-dimensional
models have shown or refuted close conformational prox-
imity of extracellular residues important for autoantibody
binding, such as in MOG and AQP4 [33, 40, 51]. Although
three-dimensional structures of human D2R [26] and D3R
[10] have been reported, neither of these two studies
included the N-terminus domain due to the difficulty
in interpreting the N-terminus density. Consequently,
although epitope conformation is essential for anti-D2R
antibody binding as observed by the loss of antibody rec-
ognition in peptide-based ELISA (K. Pathmanandavel and
F. Brilot, unpublished), spatial contribution of the six main
amino acids cannot be deciphered. Interestingly, as in
AQP4 [55], formation of supramolecular quaternary high-
order receptor mosaics have been predicted for GPCRs,
such as D2R [9], and may also influence the specific target
of D2R by autoantibodies.
Many mechanisms are likely to cause brain auto-
immunity. Molecular mimicry, whereby pathogens
express antigens that share structural homology with
self-antigens and initiate an immune response against
both the pathogen and self-antigen [18, 38], has been
reported in other neurological diseases [27, 46, 52]. Fur-
thermore, three recombinant antibodies isolated from a
patient with Sydenham chorea displayed cross-reactivity
between group A streptococcus and amino acids 1 to 20,
and to a lesser extent 21 to 37, of D2R using linear pep-
tides and ELISA [7, 12]. Interestingly, residues 20 to 29,
encompassing the six immunodominant amino acids at
position 20, 21, 22, 23, 26, and 29, showed sequence
homology with residues 55 to 64 of a unknown protein
of Penicillium roqueforti FM164, a fungus typically
found in soil, decaying organic matter, and industrial
production of blue cheese and flavoring agents
(Additional file 1: Figure S6). Future investigations are
needed to assess the role of molecular mimicry in anti-
D2R antibody autoimmunity.
Conclusion
Defining the pathogenic anti-D2R antibody antigenic re-
gion could assist the design of novel specific immuno-
therapies aimed at preventing interaction between D2R
N-terminus and autoantibodies. For example, elimin-
ation of autoantigen-specific B cells, recently demon-
strated in an animal model of diabetes, has been shown
as a potential antigen-specific therapy [23]. Other exam-
ples include the blockade of pathogenic antibodies by
binding competition with nonpathogenic antibodies [50],
and the “decoy antigen therapy”, based on a soluble spe-
cific antigen binding to autoantibodies, thus preventing
binding to their cognate target [4, 16].
Our study reports for the first time the role of D2R
N-terminus in steady state and in disease via its specific
binding to pathogenic autoantibodies, and this may be
translated into novel treatment options and improved
patient outcome.
Additional file
Additional file 1: Figure S1. a, b Anti-D2R antibody-positive movement
and psychiatric disorder (MPD) protein G-purified IgG from patient does not
induce a downregulation of surface D2R on live cells compared to IgG purified
from control (CTL) after 30 min at room temperature or 37 °C. c Anti-D2R
antibody-positive MPD protein G-purified IgG-incubated on live cells have a
similar expression of cytoplasmic GFP compared to IgG purified from control
(CTL) after 30 min at room temperature or 37 °C. Representative images are
shown (scale bar = 25μm). 15-18 different cells for each control and patient
out of two independent experiments are shown. Figure S2. Compared to
WT D2R-immunoabsorbed MPD sera, NTermD1RχD2R-immunoabsorbed
MPD sera had a higher binding to WT D2R-transfected HEK293 cells.
Representative data out of two independent experiments is shown.
Figure S3. Live L Δ2-22 D2R-transfected HEK293 cells were not
immunolabeled, by the commercial antibody (Sigma; clone 1B11).
Representative data out of three independent experiments is shown.
Figure S4. a Alignment of extracellular N-terminal 37 amino acids of N5Q/
N17Q/N23Q and WT D2R. b Confocal images of live and fixed/permeabilized
N5Q/N17Q/N23Q-transfected HEK293 cells after immunolabeling with anti-HA
antibody. Mutations of all three N-glycosylation sites led to low surface
expression and intracellular sequestration of the mutant (scale bar = 50 μm).
Figure S5. Amino acids 1-37 of D2R extracellular N-terminus aligned in 12
different animal species to highlight conserved sequences in mammals
(yellow). Amino acid sequences derived from Uniprot database and Uniprot
code for the different species. Figure S6. Sequence homology between
human D2R (20-29) and an unknown protein of the fungus Penicillium
roqueforti FM164 (55-64) was identified using the protein–protein Basic Local
Alignment Search Tool from National Center for Biotechnology Information.
Bolded residues represent identical residues between the two sequences.
Underlined residues represent immunodominant amino acids in D2R
N-terminus. (PDF 53400 kb)
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